Publication details

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

Authors

HOLZEROVÁ Milena FABER Edgar VESELOVSKÁ Jitka URBÁNKOVÁ Helena BALCÁRKOVÁ Jana ROŽMANOVÁ Šárka VOGLOVÁ Jaroslava MUŽÍK Jan CHROUST Karel INDRÁK Karel JAROŠOVÁ Marie

Year of publication 2009
Type Article in Periodical
Magazine / Source Cancer Genetics and Cytogenetics
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords CML; imatinib; chromosomal changes
Description Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.

You are running an old browser version. We recommend updating your browser to its latest version.

More info